AI Summary & Key Takeaways
AI InsightConclusion: Preclinical studies have shown that murine antihuman monoclonal antibody against Vascular Endothelial Growth Factor (VEGF) have promising activity in many gynecologic and non-gynecologic human tumors.
📌 3 Key Takeaways
Özet
Öz Purpose: The aim of our study is to determine the effects of an antiangiogenic agent (bevacizumab) in combination with or without classic chemotherapeutics on the endometrium carcinoma and use these information in our clinic practice. Materials and Methods: In vitro tests were done to determine the cytotoxic and apoptotic effects of Cisplatin, Adriablastine and Bevacizumab. Cytotoxic effect was determined by the standard MTT assay (Tetrozolium Test) and apopthosis by DAPI staining, caspase-3 on human endometrium cancer cell culture (Ishikawa). Results: The MTT assay determined that 9.6 mg/ml dose of bevacizumab caused a higher rate of decrease in cell number on Ishikawa cells compared to the highest doses of Cisplatin and Adriablastine. Therewithal, when Bevacizumab, Cisplatin, and Adriablastine were applied together for 24 hours, the number of cells decreased with an increasing dose. With the use of the triple combination with DAPI staining, it is seen that the cell silhouettes are effaced and the findings indicating apoptosis become more apparent. When bevacizumab was applied alone, the caspase 3 activity it produced was ascertained to be higher than the other two drugs individually and in combination. Caspase-3 activity was ascertained to have increased significantly as a result of the collective usage of 40 µM Cisplatin + 20 µM Adriablastine + 9.6 µgram / ml Bevacizumab, and this was found to be the highest cytotoxic activity compared to other applications. Conclusion: Preclinical studies have shown that murine antihuman monoclonal antibody against Vascular Endothelial Growth Factor (VEGF) have promising activity in many gynecologic and non-gynecologic human tumors.